STOCK TITAN

Cocrystal Pharma (COCP) SEC Filings, Oct-Dec 2025

COCP NASDAQ

Cocrystal Pharma, Inc. filings document material-event disclosures for a clinical-stage antiviral drug developer. Recent 8-K reports furnish press releases on CDI-988, including norovirus program updates, FDA Fast Track designation, scientific conference presentations and annual financial results tied to the antiviral pipeline.

The company’s filings also record Nasdaq Capital Market status, board and executive compensation matters under the 2025 Equity Incentive Plan, stock-option grants and director changes, along with Regulation FD disclosures and exhibits related to clinical and business updates.

Rhea-AI Summary

Cocrystal Pharma, Inc. reported that an Institutional Review Board at Emory University School of Medicine has approved initiation of a Phase 1b human challenge study with its compound CDI-988. The planned study is designed to evaluate CDI-988 both as a preventive and as a treatment for norovirus infections, a common cause of viral gastroenteritis. The company disclosed this development via a press release furnished as an exhibit to the report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
current report
-
Rhea-AI Summary

Cocrystal Pharma (COCP) insider Phillip Frost reported an equity transaction involving 20,000 shares of common stock at a weighted average price of $0.9406 per share on 11/25/2025. The filing shows these shares as indirectly owned through Frost Gamma Investments Trust, bringing his indirect beneficial ownership via that trust to 1,699,551 shares after the transaction. He also reports direct beneficial ownership of 27,100 shares of common stock, which includes shares issuable upon vesting of restricted stock units. Frost is identified as both a director and a 10% owner of Cocrystal Pharma, and the filing clarifies that he disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended September 30, 2025 and provided business updates. The company issued a press release on November 14, 2025 detailing these quarterly results and updates, and attached that release as Exhibit 99.1.

The report specifies that the earnings information under Item 2.02 and in Exhibit 99.1 is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless expressly stated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
Rhea-AI Summary

Cocrystal Pharma (COCP) reported Q3 2025 results showing a net loss of $2.049 million and operating expenses of $2.089 million, reflecting sharp year‑over‑year cost reductions. For the nine months, net loss was $6.405 million as R&D spending eased following completion of a Phase 2a influenza study and Phase 1 norovirus/coronavirus trial work.

Liquidity remains tight. Cash and restricted cash were $7.804 million as of September 30, 2025, after using $6.456 million in operating cash year‑to‑date. Management stated there is “substantial doubt” about continuing as a going concern. To bolster funds, the company raised net $4.183 million in a September 12, 2025 registered direct offering (with concurrent private warrants) and $154,000 via ATM sales. Subsequent to quarter end, insiders purchased 739,426 units for gross proceeds of $1.03 million on October 28, 2025.

Pipeline updates: Oral CC‑42344 for influenza A completed Phase 2a with favorable safety. CDI‑988 completed Phase 1 with tolerability across doses up to 1,200 mg; the FDA cleared a Phase 1b norovirus challenge study, expected to begin in the first half of 2026. The company also reported a $500,000 NIH/NIAID SBIR Phase I award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
quarterly report
-
Rhea-AI Summary

Cocrystal Pharma (COCP) reported insider activity by Phillip Frost, M.D., a director and 10% owner, on 10/28/2025. He acquired 359,713 shares of common stock at $1.39 per unit, with each unit also including a warrant to purchase two shares. He also acquired 719,426 warrants with a $1.24 exercise price, which were exercisable upon issuance and expire on 01/28/2028. The transaction was approved by a Special Committee under Rule 16b-3.

Following these transactions, Frost beneficially owned 1,679,551 shares indirectly through Frost Gamma Investments Trust, and 27,100 shares directly, which include shares issuable upon vesting of restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma (COCP): director-affiliated entity reports purchase

Caret Group, LLC, a director of Cocrystal Pharma, reported buying 359,713 shares at $1.39 per unit on 10/28/2025. Each unit included one share and a warrant to purchase two shares. The filing shows 719,426 warrants acquired with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028.

Following the transaction, the reporting person beneficially owned 1,383,009 shares. This total includes shares issuable upon vesting of restricted stock units, as noted in the filing’s footnote.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

Cocrystal Pharma (COCP) director Richard Pfenniger reported a purchase on 10/28/2025. He acquired 20,000 shares of common stock as part of units priced at $1.39 per unit, with each unit consisting of one share and a warrant to buy two shares. He also acquired 40,000 warrants with an exercise price of $1.24 and an expiration of 01/28/2028; the warrants were exercisable upon issuance.

Following the transactions, he beneficially owned 31,400 shares directly, which includes shares issuable upon vesting of restricted stock units. The purchase was approved by a Special Committee of the Board under Rule 16b-3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma (COCP) reported an insider purchase by a senior officer. On 10/28/2025, the reporting person acquired 3,598 shares of common stock at $1.39 per unit, with each unit also including warrants to buy two shares. The filing also shows acquisition of 7,196 warrants with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028. Following the transactions, beneficial ownership stands at 44,167 shares held directly, which includes shares issuable upon vesting of restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
-
Rhea-AI Summary

Cocrystal Pharma entered a private placement with four accredited insiders, selling 739,426 units at $1.39 per unit. Each unit includes one common share and a warrant to buy two shares at $1.24 per share for 27 months. The transaction generated $1.03 million in gross proceeds.

The sale was conducted at-the-market under Nasdaq rules and carried no registration rights. The offering relied on Section 4(a)(2) and Rule 506(b) exemptions. If fully exercised, the warrants would be exercisable for 1,478,852 additional shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
current report
Rhea-AI Summary

Cocrystal Pharma (COCP) filed an 8-K stating it announced receipt of a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). The announcement was made on October 27, 2025.

The company furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is not incorporated by reference into other filings. Cocrystal’s common stock trades on the Nasdaq Capital Market under the symbol COCP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
current report

FAQ

How many Cocrystal Pharma (COCP) SEC filings are available on StockTitan?

StockTitan tracks 57 SEC filings for Cocrystal Pharma (COCP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cocrystal Pharma (COCP)?

The most recent SEC filing for Cocrystal Pharma (COCP) was filed on November 16, 2026.